Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 3
2008 5
2009 2
2010 3
2011 8
2012 6
2013 3
2014 8
2015 16
2016 16
2017 13
2018 15
2019 21
2020 16
2021 15
2022 27
2023 25
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Results by year

Filters applied: . Clear all
Page 1
Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer.
Zhang Y, Zhou L, Xu Y, Zhou J, Jiang T, Wang J, Li C, Sun X, Song H, Song J. Zhang Y, et al. Angiogenesis. 2023 Feb;26(1):1-18. doi: 10.1007/s10456-022-09839-4. Epub 2022 May 3. Angiogenesis. 2023. PMID: 35503397
SMYD2 promotes CRC angiogenesis in vitro and in vivo. Mechanistically, SMYD2 physically interacts with HNRNPK and mediates lysine monomethylation at K422 of HNRNPK, which substantially increases RNA binding activity. ...H3K4me3 maintained by PHF8 mediates the abnorm
SMYD2 promotes CRC angiogenesis in vitro and in vivo. Mechanistically, SMYD2 physically interacts with HNRNPK and mediates lys
Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X, Jiang XJ, Fang ZM. Yi X, et al. Clin Epigenetics. 2019 Aug 1;11(1):112. doi: 10.1186/s13148-019-0711-4. Clin Epigenetics. 2019. PMID: 31370883 Free PMC article. Review.
Since aberrant SMYD2 expression and its dysfunction are often closely related to multiple diseases, SMYD2 is a promising candidate for the treatment of these diseases, such as cardiovascular disease and cancer. Here, we present an overview of the complex biology of …
Since aberrant SMYD2 expression and its dysfunction are often closely related to multiple diseases, SMYD2 is a promising candi …
SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity.
Tang M, Chen G, Tu B, Hu Z, Huang Y, DuFort CC, Wan X, Mao Z, Liu Y, Zhu WG, Lu W. Tang M, et al. Sci Adv. 2023 Jun 16;9(24):eade6624. doi: 10.1126/sciadv.ade6624. Epub 2023 Jun 14. Sci Adv. 2023. PMID: 37315132 Free PMC article.
However, this phenomenon is poorly understood. We report that methyltransferase SMYD2 plays an essential role in nonhomologous end joining repair (NHEJ), driving tumor cells adaptive to radiotherapy. ...Our study reveals an unidentified role of SMYD2 in regulating N …
However, this phenomenon is poorly understood. We report that methyltransferase SMYD2 plays an essential role in nonhomologous end jo …
SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
Xu K, Ding J, Zhou L, Li D, Luo J, Wang W, Shang M, Lin B, Zhou L, Zheng S. Xu K, et al. Cells. 2022 Dec 21;12(1):25. doi: 10.3390/cells12010025. Cells. 2022. PMID: 36611819 Free PMC article.
Our in vitro and in vivo results showed that the depletion of SMYD2 inhibits HCC cell growth. Mechanistically, c-Myc methylation by SMYD2 increases its protein stability through the ubiquitin-proteasome system. ...GLS1 plays an important role in SMYD2-mediate …
Our in vitro and in vivo results showed that the depletion of SMYD2 inhibits HCC cell growth. Mechanistically, c-Myc methylation by …
Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J, Wan F, Zhang J, Zheng S, Yang Y, Hong Z, Dai B. Li J, et al. Mol Carcinog. 2023 Jul;62(7):940-950. doi: 10.1002/mc.23536. Epub 2023 Apr 10. Mol Carcinog. 2023. PMID: 37036190
SMYD2 knockdown cells were established to identify the effects of SMYD2 on cell growth in vitro and in vivo. ...SMYD2 specific inhibitor-AZ505 was used to pharmacologically inhibit SMYD2 function in vitro and in vivo. ...
SMYD2 knockdown cells were established to identify the effects of SMYD2 on cell growth in vitro and in vivo. ...SMYD2 s
SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin.
Zhou Y, Sharma S, Sun X, Guan X, Hou Y, Yang Z, Shi H, Zou MH, Song P, Zhou J, Wang S, Hu Z, Li C. Zhou Y, et al. Cell Mol Life Sci. 2023 Aug 24;80(9):264. doi: 10.1007/s00018-023-04883-9. Cell Mol Life Sci. 2023. PMID: 37615725
Using an SMC-specific SMYD2 knockout mouse model, we found that SMYD2 ablation in VSMCs exacerbated neointima formation after vascular injury in vivo. ...In addition, myocardin directly interacted with SMYD2, thereby facilitating SMYD2 recruitment to t …
Using an SMC-specific SMYD2 knockout mouse model, we found that SMYD2 ablation in VSMCs exacerbated neointima formation after …
Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.
Su H, Meng C, Xu J, Su Z, Xiao C, Yang D. Su H, et al. Cell Death Dis. 2022 Oct 21;13(10):890. doi: 10.1038/s41419-022-05321-7. Cell Death Dis. 2022. PMID: 36270984 Free PMC article.
Both Smyd2 siRNA and LLY-507, an inhibitor of Smyd2, were used to examine the effect of Smyd2 on adipogenesis and adipocyte differentiation in vitro. Smyd2 heterozygous knockout (Smyd2(+/-)) mice were also constructed to validate the relationshi …
Both Smyd2 siRNA and LLY-507, an inhibitor of Smyd2, were used to examine the effect of Smyd2 on adipogenesis and adipo …
SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Wu L, Kou F, Ji Z, Li B, Zhang B, Guo Y, Yang L. Wu L, et al. Cell Death Dis. 2021 May 2;12(5):439. doi: 10.1038/s41419-021-03720-w. Cell Death Dis. 2021. PMID: 33935284 Free PMC article.
SMYD2 expression was significantly upregulated in LUAD cell lines and tissues. ...SMYD2 might be a prognostic biomarker and therapeutic target in LUAD....
SMYD2 expression was significantly upregulated in LUAD cell lines and tissues. ...SMYD2 might be a prognostic biomarker and th
STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.
Pan K, Hu B, Wang L, Yuan J, Xu W. Pan K, et al. J Mol Neurosci. 2022 Sep;72(9):2030-2044. doi: 10.1007/s12031-022-02051-5. Epub 2022 Aug 8. J Mol Neurosci. 2022. PMID: 35939202
SET and MYND domain-containing protein 2 (SMYD2) is an important epigenetic regulator that methylates histone and non-histone proteins. ...High SMYD2 expression correlated with a high WHO stage (P = 0.004) and a low survival probability (P = 0.012). ...
SET and MYND domain-containing protein 2 (SMYD2) is an important epigenetic regulator that methylates histone and non-histone protein …
Lysine methyltransferase SMYD2 inhibits antiviral innate immunity by promoting IRF3 dephosphorylation.
Wu J, Hu Y, Song J, Xu J, Zhang Q, Chai Y, Wang X, Wang B, Zhao Y, Cao X, Xu X. Wu J, et al. Cell Death Dis. 2023 Sep 6;14(9):592. doi: 10.1038/s41419-023-06118-y. Cell Death Dis. 2023. PMID: 37673879 Free PMC article.
The Smyd2-deficient mice are more resistant to viral infection by producing more IFN-I and proinflammatory cytokines. ...Our study identifies SMYD2 as a negative regulator of IFN-I production against virus infection. ...
The Smyd2-deficient mice are more resistant to viral infection by producing more IFN-I and proinflammatory cytokines. ...Our study id …
191 results